Incb050465

Other Medications

EU Experimental ES Not available 1 Clinical Trials

Description

INCB050465 is an experimental drug being studied by Incyte Corporation. It is currently in Phase 1 clinical trials for various advanced solid tumors, including some types of colorectal cancer (specifically MSI-high or MMR-deficient tumors). This drug is being tested in combination with pembrolizumab (an immunotherapy drug) and sometimes with itacitinib (another experimental drug). The trials are designed to determine the right dose and how safe the combination is. It is not yet approved for treating colorectal cancer or any other condition.

Mechanism of Action

INCB050465 is a PI3K-delta inhibitor. PI3K-delta is a protein involved in cell signaling pathways that can promote cancer cell growth and survival. By inhibiting this protein, INCB050465 aims to disrupt these pathways and potentially slow down or stop cancer growth. The specific molecular target is being characterized in clinical trials.

Side Effects

As INCB050465 is still in early-phase clinical trials (Phase 1) The full range of potential side effects is still being evaluated. Side effects observed in early trials often include those related to the drug's mechanism or the combination therapy But specific data for INCB050465 alone or in combination in CRC patients is limited. Common side effects for PI3K inhibitors can include fatigue Rash Diarrhea And changes in blood counts. Patients participating in clinical trials are closely monitored for any adverse events.

Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.

Clinical Trials

NCT02646748 Phase 1
Archived
Pembrolizumab Combined With Itacitinib (INCB039110) and/or Pembrolizumab Combined With INCB050465 in Advanced Solid Tumors
United States

Quick Info

CategoryOther Medications
EU EMA StatusExperimental
ES Spain AccessNot available
Clinical Trials1
View Clinical Trials Back to Drug Glossary

Related Medications

Uracil
Other Medications
786 trials
Leucovorin
Other Medications
647 trials
Paclitaxel
Other Medications
54 trials
Trifluridine
Other Medications
50 trials
Cyclophosphamid
Other Medications
50 trials
Cyclophosphamide
Other Medications
49 trials

Medical Disclaimer

This information is for educational purposes only and should not replace professional medical advice. Always consult your healthcare team before making treatment decisions.